Adipotide

Adipotide Metabolic & Systemic Energy Profile

Adipotide is fundamentally integrated into the modulation of mammalian metabolism, forcing biological networks toward lipolysis, enhanced ATP synthesis, and profound systemic energy mobilization.

Pharmacological Architecture

Parameter	Value
Molecular Formula	C152H252N44O42
Molecular Mass	2611.1 g/mol
Assay Purity	>98.0%
Appearance	Heavy white powder

Figure 1: Cellular Action of Adipotide

Metabolic Transduction Pattern

Detailed cascade of actions governing its systemic thermogenic profile:

1. Classified as a sophisticated, targeted proapoptotic (cell-death inducing) peptidomimetic.
2. Designed to seek out and bind only to prohibitin molecules on specifically white fat cell blood vessels.
3. Physically strips the blood supply away from active adipose tissue colonies.
4. Forces rapid, massive programed cell death (apoptosis) in fat cells due to pure starvation.
5. Shrinks overall adipose volume and triggers extreme, rapid systemic weight loss.

Figure 2: Rate of Systemic Lipolysis & Output

Primary Research Results

• Outcome 1: Considered 'nuclear option' phase research for reversing extreme diet-induced obesity.
• Outcome 2: Causes direct destruction of the fat cells themselves, rather than just emptying them.
• Outcome 3: Produces extremely rapid, measurable metabolic weight drops in primate models within 28 days.

Vascular-Targeted Proapoptotic Peptide

Adipotide (CKGGRAKDC-GG-D(KLAKLAK)2) is a chimeric peptide composed of two functional domains connected by a glycine-glycine linker. The targeting domain (CKGGRAKDC) is a cyclic peptide that selectively binds prohibitin, a receptor protein overexpressed on the endothelial surface of blood vessels supplying white adipose tissue. The killing domain (D(KLAKLAK)2) is a D-amino acid proapoptotic sequence that disrupts mitochondrial membranes upon internalization. Together, they create a vascular-targeted agent that selectively destroys the blood supply feeding fat deposits.

1. The CKGGRAKDC motif binds prohibitin on the luminal surface of adipose tissue endothelium with high selectivity—prohibitin is specifically upregulated on fat vasculature compared to other vascular beds.
2. Following receptor-mediated endocytosis, the D(KLAKLAK)2 domain inserts into the mitochondrial outer membrane of the endothelial cell.
3. Mitochondrial membrane potential collapses, triggering cytochrome c release and caspase-dependent apoptosis of the endothelial cell.
4. Loss of vascular supply causes ischemic death of the dependent adipocytes, resulting in focal fat depot regression.
5. The D-amino acid composition of the killing domain confers protease resistance, ensuring the peptide remains active during intracellular trafficking.

Preclinical Research & Considerations

• Primate Study: The landmark study (Kolonin et al., Nature Medicine, 2004; expanded by Barnhart et al., Science Translational Medicine, 2011) showed obese rhesus macaques lost 11% body weight in 28 days of daily adipotide treatment.
• Body Composition: Fat loss was confirmed by DEXA scanning; lean mass was preserved. Abdominal fat showed preferential reduction over subcutaneous fat.
• Renal Effects: Reversible renal proximal tubule changes were observed in primate studies, attributed to peptide filtration and tubular reabsorption. Renal function normalized upon cessation.
• Irreversibility: Unlike pharmacological fat loss, vascular ablation of adipose tissue is theoretically permanent—destroyed adipocytes and their vasculature do not regenerate.
• Research Status: Adipotide remains a preclinical research compound. No human clinical trials have been completed. All available data derives from rodent and nonhuman primate studies.